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Abstract
Monitoring cholesterol levels is strongly recommended to identify patients at risk for myocardial infarction. However, clinical
markers beyond ‘‘bad’’ and ‘‘good’’ cholesterol are needed to precisely predict individual lipid disorders. Our work
contributes to this aim by bringing together experiment and theory. We developed a novel computer-based model of the
human plasma lipoprotein metabolism in order to simulate the blood lipid levels in high resolution. Instead of focusing on a
few conventionally used predefined lipoprotein density classes (LDL, HDL), we consider the entire protein and lipid
composition spectrum of individual lipoprotein complexes. Subsequently, their distribution over density (which equals the
lipoprotein profile) is calculated. As our main results, we (i) successfully reproduced clinically measured lipoprotein profiles
of healthy subjects; (ii) assigned lipoproteins to narrow density classes, named high-resolution density sub-fractions (hrDS),
revealing heterogeneous lipoprotein distributions within the major lipoprotein classes; and (iii) present model-based
predictions of changes in the lipoprotein distribution elicited by disorders in underlying molecular processes. In its present
state, the model offers a platform for many future applications aimed at understanding the reasons for inter-individual
variability, identifying new sub-fractions of potential clinical relevance and a patient-oriented diagnosis of the potential
molecular causes for individual dyslipidemia.
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Introduction
Lipids are almost insoluble in aqueous media such as blood
plasma and thus transported among the various tissues by water-
soluble complexes called lipoproteins (LP). Elucidating the kinetic
mechanisms involved in the formation, degradation and mutual
interconversion of plasma lipoproteins is of high medical relevance
as long-term perturbations of the lipoprotein distribution are
considered the primary risk factor for atherosclerosis and
cardiovascular diseases—the main cause of death in the western
states [1]. Each lipoprotein complex contains a discrete number of
apolipoproteins (e.g. apolipoprotein B-100) and lipid molecules
(e.g. triglycerides, cholesterol), the number of which may vary
between one and several hundreds or thousands, respectively.
Basically, an enormous lipoprotein heterogeneity results from all
possible stoichiometric combinations of lipid and apolipoprotein
molecules. Despite this fact, for almost half a century, lipoproteins
have usually been grouped into density classes named chylomicrons,
VLDL, IDL, LDL, and HDL (very low-, intermediate-, low-, and
high-density lipoproteins, respectively), separated by, for example,
ultracentrifugation from blood plasma [2]. Accordingly, mathemat-
ical models of the systemic lipoprotein metabolism hitherto have
considered lipoprotein density classes (compartments) to be dynamic
variables of the system. The phenomenological transition rates
between these compartments are usually determined by radioactive
or stable isotope tracer experiments (for reviews see [3–5]). Except
for the comprehensive compartment model proposed by
Knoblauch et al. [6], compartment models have focused on
specific parts of the lipoprotein metabolism based on kinetic
measurements with, for example, labeled apoA-I [7–10], apoA-
II [11], or apoB-100 [12–14]. Compartment models may
provide a useful phenomenological description of the lipoprotein
dynamics; however, they have some serious limitations. First,
they neglect the possible heterogeneity of lipoproteins. Actually,
a single density class comprises a huge number of lipoprotein
complexes differing in their amount of lipids and proteins—an
important fact that could be of relevance for the medical
interpretation of lipoprotein density profiles. Second, the
transition of a lipoprotein from one density class into another
is not a single process but is accomplished in a series of
successive elementary reactions in which, for example, triglyc-
erides are removed, cholesterols are taken up from tissues, and
apolipoproteins are exchanged. Therefore, phenomenological
inter-compartment transition rates can hardly be related to the
rate of the underlying molecular processes. To overcome these
limitations of compartment models, we propose here a novel
approach. It consists of the establishment of kinetic equations
governing the temporal changes of individual lipoprotein
complexes. Hence, in our modeling approach, the number of
dynamic variables is in principle given by the number of
different lipoprotein complexes that can be formed from a given
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number of apolipoproteins and lipids. From the calculated set of
individual lipoprotein complexes in the system we can compute the
distribution of lipoproteins over an arbitrary number of predefined
density classes (the lipoprotein profile). In particular, we can compute
such profiles over commonly defined density classes and compare
them with experimental profiles obtained from normolipidemic
subjects. Choosing a larger set of narrow density classes and
subdividing the calculated lipoprotein distribution in, as we call it,
high-resolution density sub-fractions (hrDS), we observe a remarkable
heterogeneity of the lipoprotein distribution within commonly
defined density classes. Finally, we calculate lipoprotein profiles
associated with a disorder in one of the underlying molecular
processes of the lipoprotein metabolism. In these simulations of
pathological situations we altered the rate constants of the LDL
receptor-mediated lipoprotein uptake, lipoprotein lipase, and
ABCA1-mediated cholesterol transport.
Results
The Model
We avoid usage of predefined density classes but characterize
lipoproteins regarding their protein and lipid composition. As
described below, the model takes into account essential lipoprotein
constituents and processes involved in the lipoprotein metabolism
in human blood plasma. However, for the sake of numerical
tractability we reduced the number of lipoprotein components to a
manageable set and simplified the kinetic processes.
Lipoprotein components. The lipoprotein complexes
considered in the model are composed of three different types of
apolipoproteins and lipids abbreviated as A, B, F, and C, T, P,
respectively. The protein components A and B are thought to
represent apoA-I (P02647, ENSG00000215756) as the primary
protein constituent of HDL and apoB-100 (P04114,
ENSG00000084674) as the characteristic apolipoprotein of
VLDL, IDL, and LDL, respectively. We ignore apoB-48 and
the related lipoprotein complexes (chylomicrons), which are
rapidly formed and degraded within several hours after food
intake. Each lipoprotein is either equipped with component A or
component B. Thus, we will use the terms A-particles and B-particles
in the following, respectively. All other apolipoproteins are lumped
together into the protein component F. The lipid components C,
T, and P represent total cholesterol (free cholesterol and
cholesteryl esters), triglycerides, and phospholipids, respectively.
The dynamics of phospholipids (P) is not explicitly modeled.
Instead, the number of phospholipid molecules in an individual
lipoprotein complex is calculated such that, together with the
apolipoproteins, full occupancy of the lipoprotein surface is
achieved (see Dataset S1 for details of calculation).
The component’s densities vary between 1.35 and 0.886 g/ml
for apolipoproteins and triglycerides, respectively. The possible
number of lipid molecules may go up to several thousands. This
results in a considerably diversity of lipoprotein complexes in the
system. With the maximal number of molecules for each
component given in Table 1, we would get 8.06108 lipoprotein
complexes in total. Thus, to keep the model tractable we refrained
from considering the actual number of molecules for total
cholesterol (C) and triglycerides (T). Instead, their content was
quantified in terms of lipid packages. The package size has to be
chosen carefully to avoid sparsely occupied density ranges. In the
calculations below, lipid packages of C and T comprise 2
molecules in A-particles and 20 molecules in B-particles,
respectively.
Kinetic processes. From the reactions reported to affect the
lipoprotein metabolism in human blood plasma we selected 20
elementary processes. As we lump together free cholesterol and
cholesteryl ester into one component (total cholesterol),
esterification of free cholesterol by the lecithin-cholesterol
acyltransferase (LCAT, EC 2.3.1.43, P04180,
ENSG00000213398) is not considered. A summary of the
kinetic processes included in the model and their physiological
meaning is given in Dataset S2. For a schematic representation see
Figure 1. We grouped the processes into six categories: (1) Birth
and death: the total amount of lipoprotein complexes is the result
of de novo synthesis by the liver and the receptor-mediated uptake
of whole particles from the blood by tissue cells (Figure 1A).
Separate kinetic parameters are used for the generation and
Table 1. Composition properties of lipoprotein complexes.
Lipoprotein species Component Particle Number
A B F C T
A particle Min 1 0 0 0 0
Max 4 0 15 300 50
Initial 1 0 0 10 0
B particle Min 0 1 0 0 0
Max 0 1 15 5000 10,000
Initial 0 1 10 2000 10,000
Min and Max represent the lower and upper limit of component’s number,
respectively. Initial displays the initial composition of newly synthesized
lipoprotein particles. Lipid (C,T) package sizes were defined as 2 and 20
molecules in A- and B-particles, respectively. Thus, in terms of packages, initial
A-particles contain 5 packages of cholesterol molecules, and initial B-particles
contain 100 cholesterol and 500 triglyceride packages.
doi:10.1371/journal.pcbi.1000079.t001
Author Summary
Lipids such as cholesterol and triglycerides, which are
synthesized in the body or taken up by food, are
indispensable for each cell of the human body. They are
transported in blood plasma among the various tissues by
so-called lipoproteins, which differ in size as well as in their
composition of lipids and proteins. Changes in the amount
of certain lipoprotein fractions are considered a major risk
factor for atherosclerosis and cardiovascular diseases
(CVD)—the main cause of death in the western states.
To identify patients at risk for CVD, major lipoprotein
classes (‘‘bad’’ LDL, ‘‘good’’ HDL) are routinely monitored in
clinical practice (which equals the lipoprotein profile). In
this paper, we present a mathematical model that allows
us to calculate lipoprotein profiles by computer and to
simulate how the numerous biochemical processes
involved in the metabolism of plasma lipoproteins
influence the lipoprotein profile. Our simulations success-
fully reproduce clinically measured lipoprotein profiles of
healthy subjects and patients with a defined lipid disorder
(dyslipidemia). Calculation of a lipoprotein profile that fits
best to the profile measured in individual patients opens
the possibility of diagnosing potential molecular causes for
dyslipidemia. The results of our model calculations also
suggest the existence of lipoprotein sub-fractions which
hitherto remained unrecognized in routinely performed
separation of lipoprotein fractions. If this finding could be
validated in forthcoming experimental investigations, it
might help to define better patient-specific risk predictors
of CVD.
Predicting Plasma Lipoprotein Profiles
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elimination of A- and B-particles. The initial composition of
newly synthesized particles was set to fixed values given in
Table 1. (2) Lipoprotein-tissue exchange: besides the synthesis
and uptake of whole lipoprotein complexes (see Category 1),
individual components are selectively altered by exchange
processes with various tissue cells. The uptake of peripheral
cholesterol by A-particles and the release of cholesteryl esters
from both particle species are taken into account (Figure 1B). (3)
Inter-lipoprotein exchange of neutral lipids among lipoproteins
is mediated by the cholesteryl ester transfer protein (CETP;
P11597, ENSG00000087237), which transfers preferentially
cholesteryl esters from A- to B-particles and triglycerides and
vice versa. To model this transfer, we introduce a non-lipid
bound form of this carrier protein (called CETP(0) in the model)
that can be loaded either with C (called CETP(C)) or T (called
CETP(T)) which shuttles between A- and B-particles (Figure 1C).
The transfer of triglycerides between B-particles is included as
well and defined as a separate process. (4) Exchange of
apolipoprotein A. The transfer of apolipoproteins that can be
exchanged among lipoprotein complexes is modeled by
decomposing it into (i) a release step from a lipoprotein
complex into a common plasma pool of free apolipoprotein
and (ii) an uptake process from this pool into a lipoprotein
complex. The transfer process for the protein component A is
restricted to A-particles and is thought to describe the re-
modeling of apoA-containing HDL (Figure 1D). (5) Exchange of
apolipoproteins F. The transfer of those apolipoproteins, mostly
apoE (P02649, ENSG00000130203) and apoC, lumped together
into the component F may take place between arbitrary
lipoprotein complexes (Figure 1E). (6) Enzymatic conversion.
One central enzymatic process effecting the re-modeling of
lipoproteins is the hydrolysis of lipoproteins’ triglycerides and
phospholipids. This process is catalyzed by the lipoprotein lipase
(LPL; EC 3.1.1.34, P06858, ENSG00000175445) or the hepatic
lipase (HL; EC 3.1.1.3, P11150, ENSG00000166035), which are
treated in the model as two separate processes (Figure 1F).
Figure 1. Schematic representation of the kinetic processes modeled. (A) Synthesis of A- and B-particles and degradation via HDL and LDL
receptors, respectively. (B) Influx of peripheral cholesterol (‘‘C’’) into A-particles via the ATP-binding cassette A1 (ABCA1) receptor and selective efflux
of cholesteryl ester (‘‘C’’) by the scavenger receptor B1 (SR-B1). (C) Elementary processes of the cholesteryl ester transfer protein (CETP) mediating the
exchange of triglycerides (‘‘T’’) and cholesteryl ester (‘‘C’’) between lipoprotein components. CETP(0), CETP(T), and CETP(C) represent non-lipid–
bound, T- and C-loaded forms of CETP, respectively. (D, E) Exchange of apolipoproteins (‘‘A,’’ ‘‘F’’) among lipoprotein complexes via plasma pools
(PoolA, PoolF). (F) Hydrolysis of triglycerides (‘‘T’’) from A- and B-particles by hepatic and/or lipoprotein lipase (HL, LPL).
doi:10.1371/journal.pcbi.1000079.g001
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Stochastic Versus Deterministic Model Simulations
We modeled and simulated the system of lipoproteins by two
different approaches, a stochastic and a deterministic one. For a
detailed description the reader is referred to the Materials and
Methods section. In brief, in the stochastic simulation the
calculation of stationary lipoprotein distributions was performed
by simulating the Master equation by means of the Gillespie
algorithm until a stationary state was reached. The deterministic
model (Equation 5) governing the lipoprotein concentrations
comprises as many kinetic equations as there are different
lipoprotein complexes. However, the concentrations of most
complexes are practically zero because the elementary processes
are highly specific. Moreover, the numerical solution of very large
systems of equations poses serious numerical problems.
For the stochastic simulation of the Master equation this
enormous complexity is not a problem as the stochastic trajectories
generated by the Gillespie algorithm are located in a very small
region within the space of all possible lipoprotein complexes.
Hence, Gillespie’s direct method does not suffer from the type of
combinatorial explosion as the deterministic approach. Further-
more, using the stochastic simulation algorithm instead of the
system of differential equations permits to deal with small package
sizes for the lipid components, i.e. the number of lipid molecules
per package. Small package sizes are needed to achieve a
sufficiently high coverage of physiologically relevant density
intervals containing a number of different lipoprotein complexes.
One problem, however, with the Gillespie algorithm is to
conclude from the stochastic trajectories at which time point of the
simulation the true stationary regime has been reached and a
representative sampling of the state space has been accomplished.
To test whether the criteria used to assess stationarity work well we
have compared the concentrations calculated for one and the same
set of kinetic parameters with both simulation variants, the Gillespie
algorithm and the deterministic equation system (Figure 2).
To keep the deterministic model numerically tractable we fixed
the package sizes for cholesterol (C) and triglyceride (T) to two
molecules (A-particles) and 100 and 250 molecules (B-particles),
respectively. We also restricted the maximal number of molecules
of the components A, B, F, C and T to (4, 0, 5, 100, 40) in an A-
particle and to (0, 1, 5, 5000, 10000) in a B-particle. With the
package sizes given above, the possible C and T content of an A-
particle complex decomposes into 50 and 20 packages; for B-
particles they are 50 and 40 packages, respectively.
As the number of all components, with exception of A and B,
can become zero, the total number of different lipoprotein
complexes in this example is given by 4?(5+1)?(50+1)?(40+1) for
A-particles plus 4?(5+1)?(50+1)?(40+1) for B-particles = 38,250,
spanning a density range between 0.92 and 1.40 g/ml. Arbitrary
values of the kinetic parameters (not shown) were chosen and the
stationary concentration of lipoprotein complexes was computed
using either Gillespie’s algorithm or iterating the fix-point equation
(Equation 6).
In order to compare the two solutions we subdivided the total
density range covered by the 38,250 lipoprotein complexes into 30
intervals and calculated the occupancy of these density intervals by
cumulating the calculated concentrations of the corresponding
lipoprotein complexes. As shown in Figure 2, with increasing
number of time steps used in the Gillespie simulation the stochastic
solution of the Master equation converges toward the numerical
solution of the deterministic model.
The striking advantage of performing stochastic simulations of
the Master equation by means of Gillespie’s algorithm is that
increasing the number of lipoprotein components (e.g. by
including cholesterol ester) or using smaller package sizes results
only in a moderate increase of computing times because this
algorithm per se only deals with such lipoprotein complexes that
occur with significant concentrations. In contrast, the deterministic
model has to deal with all possible complexes despite the fact that
Figure 2. Stochastic versus deterministic simulation. Density distributions of the concentration of the sum of lipoprotein components (mg/dl)
obtained by using the Gillespie algorithm with different numbers of simulation steps (events) and by the iterative solution of the deterministic
equation system. The density space (0.93–1.35 g/ml) was subdivided into 30 equally sized intervals.
doi:10.1371/journal.pcbi.1000079.g002
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most of them never reach discernible concentrations. The
following results were obtained with the stochastic simulation
algorithm using the much smaller package size of 20 molecules for
C and T in B-particles.
Calculation of Lipoprotein Density Profiles in Healthy
Subjects
In the experiment, main density classes of lipoproteins (VLDL,
IDL, LDL, HDL) and sub-fractions of LDL and HDL were
isolated from blood plasma. The LDL class was separated into six
density sub-fractions, which are grouped into the commonly
named large buoyant (lb; LDL1/2), intermediate dense (id;
LDL3/4), and small-dense LDL (sd; LDL5/6). The HDL class
was subdivided into sub-fractions of HDL2b, HDL2a, and HDL3.
In the simulation, stationary lipoprotein distributions were
computed by using Gillespie’s stochastic simulation algorithm as
outlined in the Materials and Methods section. Simulation starts in
a system state that is lipoprotein-free. Executing approximately
five million reactions (one per time step), a steady state was
reached, i.e. the average number of lipoproteins and their
composition in the systems remained constant. An additional 10
million executions sampled the stationary distribution of individual
lipoprotein complexes. We then calculated lipoprotein density
profiles as they are typically determined in clinical investigations
by assigning each of the lipoprotein complex according to its
concentration to one of the experimentally defined density classes.
The set of model parameters that entail best agreement between
the computed lipoprotein profile and the experimental data (see
Table 2) was determined as follows. To keep the number of
lipoprotein complexes in the simulation tractable, we scaled the
system with an appropriate volume factor yielding a reaction
volume of one tenth femto-liter. Parameter values for the synthesis
of A- and B-particles were taken from [9] and [15], respectively,
and fixed during parameter optimization. Numerical values of all
other model parameters were obtained by minimizing the distance
between simulated and clinically measured lipoprotein profiles (see
Materials and Methods). They are listed in Table 3.
The estimated parameter values are in most cases in a
reasonable agreement with experimentally determined values
taking into account the difficulties to extract rate constants of
elementary processes from kinetic measurements settled on
compartment analysis. The underlying reaction mechanism can
either be monomolecular or bimolecular which is important to
know while comparing the stochastic rate constants with rate
constants obtained from tracer kinetic studies. A detailed
comparison of calculated and measured rate constants is given
in Dataset S3.
As shown in Figure 3, the calculated lipoprotein density profiles
for each of the lipoprotein components by using the parameter
values given in Table 3 are, to a large part, in a remarkable
agreement with the clinical data. However, with respect to the
distribution of apolipoprotein B (Figure 3B) and of triglycerides
(Figure 3E) some discrepancies remain.
The total amount of 41.860.45 mg/dl of component B
predicted by the model is lower than the mean value of
56.6 mg/dl determined experimentally for apoB-100, but within
the expected interval (621.4 mg/dl). Compared with experimen-
tal values the calculated concentration of apoB-100 is higher in the
VLDL sub-fraction but lower in IDL and all LDL sub-fractions.
This might be accounted by the simplifications made in our model
for the kinetics of triglyceride removal from B-particles because
regulatory influences of apolipoproteins C and E are ignored.
Likewise, the simplified kinetics of triglyceride removal from B-
particles might also explain the too low triglyceride content
predicted for the IDL sub-fraction since the high rate of
triglyceride hydrolysis obtained by the parameter optimization
procedure yields a rapid delipidation of newly synthesized B-
particles. The simplification to assume a definite initial composi-
Table 2. Experimental lipoprotein composition data.
Lp fraction Density (g/ml) Concentration, mg/dl (6SD) (n=11)
Min Max Total A B F C T P
Plasma 0.950 1.400 755.8 (102.6) 122.3 (21.7) 68.3 (17.3) 20.87 (3.8) 164.9 (30.1) 109.9 (44.6) 181.9 (23.0)
VLDL 0.950 1.006 120.9 (70.9) 0.0 5.1 (2.1) 7.12 (3.8) 17.1 (9.3) 69.5 (42.8) 22.0 (11.9)
IDL 1.006 1.019 33.4 (10.4) 0.0 3.7 (1.7) 0.54 (0.2) 8.4 (5.1) 12.1 (2.6) 8.6 (3.4)
LDL 1.019 1.063 217.34 (56.1) 0.0 47.5 (12.7) 0.45 (0.4) 89.6 (24.4) 19.7 (5.6) 60.1 (14.6)
LDL1 1.019 1.031 41.8 (12.5) 0.0 7.8 (2.2) 0.05 (0.1) 17.0 (5.9) 5.1 (1.5) 11.8 (3.5)
LDL2 1.031 1.034 30.4 (8.7) 0.0 6.2 (1.7) 0.0 13.0 (4.3) 2.5 (0.7) 8.6 (2.6)
LDL3 1.034 1.037 33.4 (10.0) 0.0 7.3 (2.2) 0.0 14.2 (4.3) 2.6 (1.1) 9.4 (2.7)
LDL4 1.037 1.040 39.7 (17.3) 0.0 9.2 (4.1) 0.0 17.0 (7.5) 2.8 (1.5) 10.8 (4.5)
LDL5 1.040 1.044 36.9 (16.8) 0.0 8.9 (4.1) 0.0 15.5 (7.2) 2.5 (1.2) 10.0 (4.5)
LDL6 1.044 1.063 33.4 (11.6) 0.0 8.4 (3.1) 0.34 (0.2) 12.9 (4.6) 3.0 (1.1) 8.8 (3.0)
HDL 1.063 1.400 216.1 (50.5) 89.4 (19.9) 0.0 5.12 (2.0) 41.8 (10.9) 10.5 (2.0 ) 64.8 (18.3)
HDL2 1.063 1.125 96.13 (33.1) 34.9 (12.0) 0.0 0.38 (0.5) 21.61 (8.0) 5.63 (1.0) 33.80 (12.9)
HDL2b 1.063 1.100 31.1 (16.8) 9.4 (5.5) 0.0 0.38 (0.4) 8.1 (4.3) 2.0 (0.4) 11.3 (6.5)
HDL2a 1.100 1.125 65.1 (18.6) 25.5 (7.3) 0.0 0.0 13.5 (4.2) 3.6 (0.8) 22.5 (7.2)
HDL3 1.125 1.210 84.2 (17.3) 42.8 (9.1) 0.0 0.48 (0.4) 14.4 (3.0) 3.6 (1.1) 23.2 (5.4)
preb-HDLa 1.210 1.400 40.8 (20.0) 30.6 (8.0) 0.0 2.57 (1.5) 0.0 0.0 29.7 (1.3)
The data are averaged values from 11 randomly selected normolipidemic subjects.
aThe density fraction of so-called preb-HDL (1.210–1.400 g/ml) was not directly measured in the experiment. We therefore assumed and calculated this fraction as the
difference between total plasma and total HDL values for apoA-I, cholesterol, and phospholipids.
doi:10.1371/journal.pcbi.1000079.t002
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tion of newly synthesized lipoproteins in the model might be
another reason for the remaining discrepancy in the distribution of
apoB-100.
The calculated distribution of model component F was
compared with the clinically measured concentration values of
the C apolipoproteins I–III and apoE. However, experimental
data for component F are questionable, as only about one-half of
the total plasma concentration of apoC and apoE (20.8763.8 mg/
dl) is associated with lipoprotein complexes. The other half reflects
a free apolipoprotein pool in plasma, whose value is about 10-fold
higher than 1.2 mg/dl reported by [16]. This might result from
experimental difficulties, because it is well documented that apoE
may dissociate from the surface of apoB-containing particles
during prolonged ultracentrifugation [17,18]. This may account
for the fact that our model predicts higher levels of component F in
almost all lipoprotein density classes as compared to the available
experimental data (Figure 3C). In fact, the calculated distribution
of F agrees much better with the experimental total plasma
concentration (19.0 mg/dl) as well as with the concentration
observed for the free plasma pool (1.2 mg/dl) by Batal et al.
Initial composition analysis. The initial composition of A-
and B-particles was kept constant during simulation (Table 1).
However, depending on a variety of factors, including nutrition or
cellular and regulatory processes, the liver generates a certain
lipoprotein spectrum of different compositions. To analyze how
the lipoprotein distribution in the blood plasma changes in
response to different initial compositions, the molecule numbers of
the lipoprotein components F, C, and T of B-particles were
randomized from a normal distribution by taking the reference
composition as the mean value. A total of 100 different initial
compositions were analyzed in independent simulation runs. The
compositions obtained by randomization provide ranges for F, C,
and T between 0–18, 760–2,934, and 6,654–14,784 molecules,
respectively. The variation of each of the random compositions
relative to the reference composition was quantified using the
euclidean distance.
Figure 4 illustrates the overall tendency, the more different the
composition from the reference value (increasing euclidean
distance) the larger the distance between the calculated and
experimental lipoprotein distributions. However, a number of
compositions considerably deviating from the default one fit
comparably well or even improve the agreement with the
experimental data (see LP composition #81 and #63, respective-
ly). In our calculations, this predominantly pertains to composi-
tions that are mainly increased in the amount of component F and
C. The results suggest that certain variability in the initial
composition can be partially compensated by the kinetic processes
in the LP metabolism. Or, the other way around, specific inter-
individual variations in the liver status are not necessarily reflected
in altered distributions of the main lipoprotein classes in the blood.
hrDS
Characterizing the distribution of lipoproteins in the blood
plasma by quantifying their abundance in a limited number of
main density classes such as chylomicrons, VLDL, IDL, LDL, and
HDL (the classical density profile) appears feasible as long as the
distribution of lipoprotein components within these classes is
sufficiently smooth. That means, any alteration in the kinetic
properties of the underlying elementary processes ultimately gives
rise to changes in the relative occupation of these density classes.
On the other hand, alterations in the kinetic processes may not
necessarily lead to visible changes in the average value of a density
class, while the concentration and composition of individual
lipoproteins within the class may vary significantly.
To reveal the heterogeneity of the lipoprotein distribution
within the main density classes experimentally used, the width of
each was decomposed into five equally sized sub-intervals.
Subsequently, we quantified the calculated amount of lipoprotein
components in these narrow density classes, for which we
introduce the name hrDS. Since the main density classes exhibit
differing density interval sizes, we normalized the distribution
within each density class to its interval size.
As an example, Figure 5 shows the distribution of cholesterol
across the hrDS, which allows to quantify the contribution of the
hrDS to the average concentration of the main classes. Most
significant intra-class variation appear in the ascending (LDL1,
LDL2 and HDL2b) and descending (LDL5, LDL6 and HDL3)
part of the overall distribution. For example, in LDL6 (density
d = 1.044–1.063 g/ml), the calculated mean concentration of
cholesterol amounts to 15.160.1 mg/dl (normalized value of
0.795 with LDL6 interval size of 19). The five hrDS named
LDL6(I), (II), (III), (IV), and (V) relatively contribute with 53.1%,
25.7%, 11.7%, 5.5%, and 4.0% to the average cholesterol
concentrations, respectively. According to this finding, more than
one-half of the cholesterol content in LDL6 is contributed by
lipoprotein complexes with densities in the narrow range of 1.044–
Table 3. Model parameter values.
Rate Constants (cm) Unit
Model
Value Exp Value Reference
A-particle ccreateA mmol/l?day
21 8.0e-3 8.4e-3 to
9.2e-3
[9,15,53]
cdestroyA day
21 0.21 0.20 [9,15,53,54]
cinflux mmol/l?day
21 1.1e-3 2.5e-3 [55]
ceffluxA day
21 0.01 0.312 [54]
cexchangeCA day
21 397.1 110.1 [56]a
cexchangeTA day
21 0.65 -
ctransferA day
21 2.0e-4 5.3e-5 [53]g
cuptakeA day
21 0.02 0.14 [53]h
ctransferFA day
21 9.4e-4 7.6e-3 [16]c
cuptakeFA day
21 1.9e-3 3.9e-3 [16]d
chydrolyzeA day
21 5.6 27.72 [57]
B-particle ccreateB mmol/l?day
21 1.0e-3 1.0e-3, 1.4e-3 [15,58]
cdestroyB day
21 1.31 0.5 - 5.5 [15]
0.4 - 6.9 [58]
ceffluxB day
21 0.5 -
cexchangeCB day
21 1.7 -
cexchangeTB1 day
21 887.75 1.2 [56]b
cexchangeTB2 day
21 55.7 -
ctransferFB day
21 2.0e-3 1.6e-3 [16]e
cuptakeFB day
21 3.5e-3 0.061 [16]f
chydrolyzeB day
21 8.3 7.52 [54]
Comparison of estimated model parameter values with measured rate
constants found in the literature.
a–hIndexes; see explanations in Dataset S3. For a and b, it might be more useful
to compare the flux values (total transfer activities, mg/dl per day), because
the literature substrate concentrations vary from that in our simulation. HDL-
CE is approximately one third and VLDL-TG is approximately double of that
in our simulation. In both cases, the CETP mass is much less even.
a72.13 vs. 110.52 mg/dl ? day21.
b297.45 vs. 15.87 mg/dl ? day21.
doi:10.1371/journal.pcbi.1000079.t003
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1.0478 g/ml. Within the other classes the hrDS are nearly equally
distributed.
The specific intra-class variations of the main density classes
show similar patterns for all the other lipoprotein components
(Figure 6). However, some intra-class distributions vary for
different components. For example, within VLDL triglycerides
and phospholipids show monotonically decreasing instead of a
nearly equal distribution (Figure 6E, F).
Figure 3. Simulated versus clinically measured distribution of lipoprotein components over main density classes including sub-
fractions of LDL1-6, HDL2b, HDL2a and HDL3. x-axis: number of lipoprotein density fraction; y-axis: simulated (circles) versus clinically
measured (rectangles) concentration values in mg/dl of Apolipoprotein A–I (A), Apolipoprotein B-100 (B), Sum of further apolipoproteins (C), Total
cholesterol (D), Triglycerides (E, logarithm) and Phospholipids (F). The error bars show the standard deviation of the experimental values.
doi:10.1371/journal.pcbi.1000079.g003
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One may hypothesize that the amount and distribution of
lipoprotein sub-populations differ between individual healthy subjects
or even in pathological conditions due to inter-individual variations.
To check whether the knowledge of the intra-class distribution
provides additional and valuable information, we moderately varied
each of the kinetic parameters by 610% of the reference value.
The results indicate that, for example, marginal alterations in
the delipidation process of B-particles (HydrolyzeB) shifts the high
resolution distribution within a major density class either to lower
or higher densities (Figure 7), while the concentration value of the
major classes (e.g., LDL) remains nearly unchanged. Similar
results were obtained for the selective cholesteryl ester uptake from
B-particles (EffluxB) and the amount of CETP available (data not
shown).
Simulated Pathological States
To check the predictive capacity of our model we simulated the
impact of disorders in the kinetic properties of the LDL-receptor
(LDLR; P01130, ENSG00000130164), the lipoprotein lipase
(LPL) and ATP-binding cassette A1 (ABCA1; O95477,
ENSG00000165029) on the stationary density distribution of
lipoproteins (Figures 8–10).
Familial Hypercholesterolemia (FH) is an autosomal
hereditary disease caused by a dysfunction of the LDLR. We
simulated a reduced LDLR activity by decreasing the parameter
for the process DestroyB to 75% of its normal value. The calculated
lipoprotein distribution exhibits an increased concentration of
LDL cholesterol at nearly unchanged cholesterol levels of VLDL
and IDL (Figure 8D). It is suggesting that this arises from lowering
the receptor-mediated uptake while maintaining a sufficient apoB-
synthesis leading likewise to elevated LDL-apoB levels (Figure 8B).
Within LDL, the sub-fractions LDL1-6 behave differently. As
compared to normolipidemic cholesterol values, we observe
moderately increased levels of idLDL-C (25.2 vs. 31.8 mg/dl,
+26%) and to a higher extent of sdLDL-C (28.7 vs. 49.2 mg/dl,
+71%) whereas lbLDL-C (26.8 vs. 24.4 mg/dl) remains nearly
unchanged. These results coincides with findings of low LDL-
cholesterol to LDL-apoB ratios in carriers of the FH-Keuruu
mutation (Asp235RGlu) suggesting that LDL particles are small
and dense [19]. The LDL subfraction pattern is also similar to
findings by Ma¨rz et al. in a patient with FDB (Familial defective
apolipoproteinB-100) who has a mutation in codon 3500 of the
apoB gene substituting glutamine for arginine [20].
Regarding the distribution of A-particles (equivalent to HDL),
the model predicts a moderate decrease in HDL cholesterol as
compared to the normolipidemic profile (Figure 8D). This is in
good agreement with the reduced overall HDL cholesterol level
observed in heterozygous FH patients [7].
Figure 4. Variation in the initial composition of B-particles. The initial composition of B-particles, i.e. the molecule numbers of component F,
C and T, was randomized. The filled black bars (x = 0) mark the default B-particle initial composition (initF = 10, initC = 2000, initT = 10000). A total of
100 different compositions (brown bars) were analyzed by independent simulation runs. The graphs are sorted by the euclidean distance (topmost
sub-graph, black dashed line). The change in the error measure (distance between calculated and experimental lipoprotein distributions) relative to
the value obtained for the default composition is shown in the topmost sub-graph (black continous line).
doi:10.1371/journal.pcbi.1000079.g004
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However, an impaired interaction between B-particles, such as
LDL, and the receptor may be due to several reasons. Either there
is indeed a defect in the receptor itself (FH) due to mutations that
cause a reduced expression or binding activity, or the ligand
(potentially apolipoprotein B-100) carries a mutation (FDB). Since
the uptake process is determined by solely one parameter in the
present model, we cannot yet discriminate between different
molecular determinants.
Hypertriglyceridemia is characterized by elevated levels of
plasma triglycerides caused, among others, by deficiencies of the
lipoprotein lipase (LPL), the key enzyme in the catabolism of
triglyceride-rich lipoproteins by removing (hydrolyzing) triglycer-
ides. We simulated the consequences of an impaired LPL activity
by lowering the parameter value for the process HydrolyzeB to one-
half of the original value.
The calculated lipoprotein distributions display markedly
elevated levels of triglycerides as well as cholesterol, predominantly
of VLDL, IDL and early LDL (Figure 9D and 9E). The total
plasma concentration of triglycerides (159.5 vs. 95.2 mg/dl) is
about 67.4% increased as compared to the simulated normolipi-
demic profile. According to our calculations, the total concentra-
tion of LDL cholesterol is only marginally affected (152 vs.
145 mg/dl), whereas substantial alterations in the cholesterol level
of individual LDL subfractions are predicted. lbLDL (LDL1+2) is
considerably increased. As compared to normolipidemic LDL
cholesterol values, we obtain a strong reduction in idLDL
(LDL3+4, 25.2 mg/dl vs. 1.8 mg/dl, 292%) and to a lower
degree of sdLDL (LDL5+6, 28.7 mg/dl vs. 5.1 mg/dl, 282%).
Elevated levels of sdLDL implicated with mild to moderate
hypertriglyceridemia cannot be found in the model simulations
[21]. Likewise, reduced HDL cholesterol are not observed as
reported by Babirak et al. for the phenotype of heterozygous LPL
deficiency [22]. In contrast, the calculated distribution shows
increased HDL cholesterol levels of HDL2b while in HDL2a and
HDL3 no discernible changes occur.
The calculated distributions might be mechanistically explained
as follows. Due to the decreased hydrolysis parameter, during
simulation, the HydrolyzeB process is executed about 1.2-fold less
leading to the accumulation of B-particles enriched in triglycer-
ides. Elevated triglyceride levels, in turn, promote the transfer of
triglycerides to A-particles mediated by the CETP (1.4-fold higher
frequency of the processes ExchangeTB and ExchangeTB).
Likewise, the more CETP is loaded with triglycerides the less
lipid-unloaded CETP is capable to transport cholesterol back from
A-particles to B-particles. Subsequently, lipoprotein complexes in
the density range of HDL become enriched in cholesterol and
triglycerides. A 1.4-fold higher frequency is also observed for the
HydrolyzeA process implicating a higher HL activity, the enzyme
that catalyzes the hydrolysis of triglycerides from small B-particles
and A-particles. That may explain the low triglyceride content in
all LDL sub-fractions.
Hypoalphalipoproteinemia is a rare human metabolic
disorder characterized by a severe decrease in HDL cholesterol
and apoA-I levels. For example, Tangier Disease (TD) is assumed
Figure 5. High-resolution distribution of total cholesterol within main density classes including sub-fractions of LDL1-6, HDL2b,
HDL2a, and HDL3. Each density class was further decomposed into 5 equally sized sub-fractions, called hrDS (grey bars). x-axis: density in g/ml; y-
axis: concentration of total cholesterol in mg/dl normalized to the density interval size.
doi:10.1371/journal.pcbi.1000079.g005
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to be caused by defects in both alleles of the ABCA1 (ATP-binding
cassette A1) transporter gene [23], the key mediator of the reverse
cholesterol transport by transferring cholesterol and phospholipids
from peripheral cells to acceptor lipoproteins in the plasma. A
heterozygous ABCA1 defect correspond to the disorder known as
familial hypoalphalipoproteinemia (FHA).
We simulated an impaired activity of ABCA1 by reducing the rate
constant for the cholesterol uptake into A-particles (process Influx) to
Figure 6. High-resolution distribution of lipoprotein components within main density classes including sub-fractions of LDL1-6,
HDL2b, HDL2a, and HDL3. Each density class was further decomposed into five equally sized sub-fractions, called hrDS (grey bars). x-axis: number
of lipoprotein density subfraction; y-axis: concentration of apolipoprotein A–I (A), apolipoprotein B-100 (B), sum of further apolipoproteins (C), total
cholesterol (D), triglycerides (E) and phospholipids (F) in mg/dl normalized to the density interval size.
doi:10.1371/journal.pcbi.1000079.g006
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50% of its normal value. Compared with simulated normolipidemic
values, the model predicts low plasma cholesterol concentrations
(144.5 mg/dl vs. 95.47 mg/dl, 234%). As reported for FHA, a
remarkable reduction of cholesterol levels appears in all HDL
fractions (Figure 10D). HDL cholesterol accounts for only,10 mg/
dl at nearly normal total plasma triglyceride levels (95.2 vs. 96.8 mg/
dl). As a consequence, considerable levels of apoA-I occur in the
density range d.1.21 g/ml which argues for the accumulation of
pre-b–migrating lipoproteins (Figure 10A). Our model simulation
predicts further a marginal reduction in apoA-I within the HDL3
fraction, while in HDL2b and HDL2a apoA-I is selectively depleted.
As comparable results from clinical studies, a predominance of HDL
particles being poor in cholesterol but enriched in apoA-I in patients
with heterozygous TD [24], [25].
The distributions of apoB, apoF, cholesterol and triglycerides of
B-particles display a shift to lipoproteins in the density range of
Figure 7. Variation in the distribution of hrDS cholesterol at moderately altered parameter values. Alteration of the normal hrDS
cholesterol distribution (grey bars) by (A) increasing and (B) decreasing the parameter value of the HydrolyzeB process by 10% of its normal value
(black bars). x-axis: metrical density intervals in g/ml; y-axis: concentration of total cholesterol in mg/dl normalized to the density interval size.
doi:10.1371/journal.pcbi.1000079.g007
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LDL6 (Figure 10B–10E). Analyzing the stochastic trajectories of our
model simulations shows that the Influx process occurred approxi-
mately 2-fold less frequent. The reduced uptake of cholesterol from
the periphery to A-particles leads to a diminished cholesterol transfer
to B-particles and to less CETP molecules loaded with cholesterol.
This forces the rate for the back transfer of triglycerides from
triglyceride-rich B-particles to A-particles or cholesterol-rich B-
particles to increase. Accordingly, the model calculations show
reduced concentrations of VLDL triglycerides and increased
triglyceride levels in, e.g. HDL3 and LDL6, respectively.
Figure 8. Calculated pathological distribution compared with calculated normal data for LDL receptor deficiency. Distributions of the
lipoprotein components in the main density classes including sub-fractions of LDL1-6, HDL2b, HDL2a and HDL3. x-axis: number of lipoprotein density
fractions; y-axis: calculated pathological (squares) and calculated normal (circles) concentration values of apolipoprotein A–I (A), apolipoprotein B-100
(B), sum of further apolipoproteins (C), total cholesterol (D), triglycerides ([E], logarithm) and phospholipids (F) in mg/dl.
doi:10.1371/journal.pcbi.1000079.g008
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Discussion
We have developed a novel computational approach toward the
calculation of lipoprotein distributions in blood plasma. The basic
idea of our concept is to model the dynamics of individual
lipoproteins instead of predefined density classes. This enables us
to include in an adequate manner the elementary reactions
involved in lipoprotein metabolism. A further benefit of our
approach is to provide a more detailed information on the lipid
and protein composition of lipoproteins than possible by using
conventional compartment models.
Figure 9. Calculated pathological distribution compared with calculated normal data for LPL deficiency. Distributions of the
lipoprotein components in the main density classes including sub-fractions of LDL1-6, HDL2b, HDL2a, and HDL3. x-axis: number of lipoprotein density
fractions; y-axis: calculated pathological (squares) and calculated normal (circles) concentration values of apolipoprotein A-I (A), apolipoprotein B-100
(B), sum of further apolipoproteins (C), total cholesterol (D), triglycerides ([E], logarithm), and phospholipids (F, logarithm) in mg/dl.
doi:10.1371/journal.pcbi.1000079.g009
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To introduce the method and to deal with a manageable set of
unknown kinetic parameters, we present in this work a simplified
core model which does not include all biochemical processes
involved in lipoprotein metabolism and which uses simplified rate
equations of the mass-action type. Therefore, it is obvious that
some inconsistencies between calculated and measured distribu-
tions of lipoprotein should occur. Nevertheless, even based on this
simplified core model we were able to simulate with remarkable
accuracy experimentally determined density profiles of lipid and
protein components in normal and pathological situations.
Figure 10. Calculated pathological distribution compared with calculated normal data for ABCA1 deficiency. Distributions of the
lipoprotein components in the main density classes, including sub-fractions of LDL1-6, HDL2b, HDL2a and HDL3. x-axis: number of lipoprotein density
fractions; y-axis: calculated pathological (squares) and calculated normal (circles) concentration values of of apolipoprotein A–I (A), apolipoprotein B-
100 (B), sum of further apolipoproteins (C), total cholesterol (D), triglycerides ([E], logarithm), and phospholipids (F) in mg/dl.
doi:10.1371/journal.pcbi.1000079.g010
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Calculated Versus Clinically Measured Lipoprotein
Profiles in Healthy Subjects
As experimental information on the composition of lipoproteins
so far is only available for the commonly defined density classes
(lipoprotein compartments) the only way to estimate unknown
parameters of the model and to compare the computations with
the experiment was to condense the calculated profiles of
individual lipoprotein complexes into density class profiles. This
way, we determined numerical values of model parameters which,
to a large degree, are in good agreement with experimental data
taken from a larger set of independent kinetic experiments.
Based on this parametrization, we computed lipoprotein density
profiles of healthy subjects. The remaining deviations pertain
mostly to the distribution of apoB-100, whose calculated
concentration is higher in VLDL and lower in the IDL and
LDL classes than measured in the blood of normolipidemic
patients. Further refinement of the model by including, for
example, the regulation of LPL activity by apolipoprotein C-II
[26] or the hepatic generation of a broader spectrum of
lipoproteins even belonging to the IDL and LDL type [14] will
certainly help to overcome this discrepancy. However, discrepan-
cies between model and experiment may at least partially also
result from experimental uncertainties.
Simulated Pathological States
The model was applied to calculate the distribution of
lipoproteins of subjects with a defined molecular defect in one of
the underlying elementary kinetic processes. Hypercholesterol-
emia, hypertriglyceridemia and hypoalphalipoproteinemia were
exemplarily simulated by modifying the corresponding model
parameters.
In all cases, the simulated pathological states could nicely
reproduce fundamental clinical characteristics of the selected
dyslipidemia. It has to be noted, that, in the present state of the
model, we cannot assign the altered lipid phenotype to different
molecular determinants of a process. For example, hypercholes-
terolemia may caused by a reduced binding constant of apoB or a
diminished expression of the apoB-binding LDL receptor.
Refining the kinetic description of the processes will be therefore
one of the tasks in future work and might allow to address defects
in different genes to a process.
Lipid Values in High Resolution
Various studies have shown that individual lipoprotein sub-
populations exhibit differing metabolic behavior. First evidence for
the existence of discrete LDL sub-populations has been reported
by Krauss and Burke [27]. More recently, also HDL has been
found to be especially complex with at least 5 and perhaps as many
as 12 or more subclasses [28] showing differing metabolic behavior
[29] and redistribution in pathological conditions [25].
Nevertheless, experimental separation and analysis is an
elaborate, time-consuming and expensive venture and not yet
worthwhile for routine measurements. Experimental methods
established for lipid fractionation include gradient density
ultracentrifugation [30–32], non-denaturing polyacrylamide gra-
dient gel electrophoresis (GGE) [33], nuclear magnetic resonance
(NMR) spectroscopy [34,35] and high performance liquid
chromatography (HPLC) [36,37], each with particular assets and
drawbacks [38]. GGE and NMR spectroscopy in particular are
capable of measuring both lipoprotein particle numbers (LDL-P)
and size. In fact, the cholesterol content per particle exhibits large
inter-individual variation, and distributions of LDL sub-classes
have been shown to vary tremendously among individuals
independent of total LDL cholesterol [39], which emphasizes the
importance of the concept presented here as the work permits to
calculate the distribution of lipoproteins across any narrow density
interval of choice and on the basis of the entire spectrum of
lipoprotein particles in plasma differing in size, composition and
physiological function.
The analysis of high-resolution lipoprotein profiles, therefore,
preferentially aim at understanding the reasons for inter-individual
variability in subjects of normal or intermediate risk state, but
possibly even in distinct pathological conditions. To this end,
experimental validation of the predicted high resolution distribu-
tion will be essential in future work.
Model Extensions and Refinements
Based on our findings, we plan to study in a systematic manner
how a re-definition of density classes and the combination of
lipoprotein component levels determined within these classes may
help to define novel diagnostic parameters which sensitively and
specifically indicate alterations of the lipoprotein metabolism on
the molecular level. However, such model-based optimization of
systemic lipid diagnostics requires extensive improvements of the
core model presented in this paper. The most relevant extensions
and refinements necessary to increase the physiological reliability
of the model are as follows: (i) inclusion of apoA-II (P02652,
ENSG00000158874) to allow for differentiation between LpA-I
and LpA-I:A-II particles to better satisfy the differing metabolic
behavior of several HDL sub-populations in normal and
pathological conditions [25,40]; (ii) inclusion of apoB-48 in
addition to apoB-100 to model the metabolism of intestinal
synthesized chylomicrons even with respect to postprandial
hyperlipidemia [41,42]; (iii) distinguishing between free cholesterol
and cholesteryl ester and inclusion of the esterification process of
free cholesterol by LCAT [43]; (iv) disaggregation of the model
component variable F into apolipoproteins E and C and explicit
consideration of the regulatory function of these isoforms (e.g.,
activating effect of apoC-I [P02654, ENSG00000130208] on
LCAT [44], activation of LPL by apoC-II [P02655,
ENSG00000213044] [26], influence on the LDL receptor binding
by apoE [45], and the apoE-dependent alternative path for
peripheral cholesterol [46]); (v) explicit incorporation of the
phospholipid exchangemediated by the phospholipid transfer protein
(PLTP; P55058, ENSG00000100979) playing a key role in the
remodeling of HDL [47,48]; and (vi) inclusion of other transporters
and receptors involved either in the holoparticle uptake or in the
uptake of individual lipoprotein components, e.g., SR-B1 (Q8WTV0,
ENSG00000073060), ABCG1 (P45844, ENSG00000160179), and
ABCG4 (Q9H172, ENSG00000172350) [49,50].
Model-Based Clinical Application
The clinical relevance of our modeling approach consists in its
capability to infer from the measured lipoprotein profile of a
patient potential alterations in one or several of the underlying
kinetic processes. Together with other independent information on
diet (affecting primarily the composition and amount of VLDL
particles generated by the liver) and genetic variations based on
SNP analysis of genes related to enzymes of the lipoprotein
metabolism this will allow to elucidate the molecular basis of
observed abnormal lipoprotein profiles.
It has to be critically noted, however, that there is no
unambiguous relationship between the conventionally measured
pattern of lipoprotein main classes (VLDL, IDL, LDL, HDL2,
HDL3) and the kinetic parameters of the kinetic processes
included in the model. In other words, different sets of kinetic
parameters may provide one and the same calculated pattern of
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main classes. One reason is that moderate changes in the kinetic
properties of a single process may cause a moderate shift in the
lipoprotein distribution that does not significantly affect the
average composition of the main classes. This has been
demonstrated by comparing our calculated lipoprotein distribution
of a normal patient and a virtual patient having a 10% lower or
higher activity of his lipoprotein lipase. The absolute amount and
lipid composition of the main density classes of both patients are
practically identical. The example also illustrates the advantage of
high-resolution profiles for making the altered lipoprotein
distribution within the main classes visible. A second reason
accounting for the above mentioned ambiguity between the
lipoprotein density profile and the kinetic parameters of the
underlying molecular processes is that simultaneous alterations in
more than one parameter may compensate each other with
respect to the resulting shape of the LP distribution. An exemplary
case was shown in that the initial composition of the VLDL
particle leaving the liver was varied and the distance of the
associated lipoprotein density profile was computed with respect to
the standard profile. Notably, there exist different initial
compositions yielding practically identical lipoprotein profiles.
For the practical application of our model this implies the
following strategy: First, vary the kinetic parameters of those
processes known to be mostly affected by genetic variations (e.g.
LDL uptake rate, LPL activity, rate of cholesterol transfer to HDL)
and/or diet (synthesis rate of a composition of VLDL) in a
physiologically reasonable range, calculate the associated LP
profiles and store them in a lipoprotein profile data base. Second,
compare the measured LP profile of a patient (the higher the
resolution, the better) with all profiles in the data base and identify
parameter constellations that would account for the patient’s
profile. Take this information as an adjunct to other independent
findings to diagnose the molecular background of the patient’s
profile.
Finally, it has to be emphasized that the model can also be used
to simulate the expected outcome of a proposed medical treatment
following the diagnostic step described above.
Conclusion
The model simulations successfully reproduce lipoprotein
composition data of common density classes from healthy subjects
and enable the revealing of the distribution of lipoproteins in high
resolution. Abnormal distributions of lipoproteins can be predicted
by modifying one of the underlying kinetic processes simulating
lipid disorders. On the other hand, lipoprotein profiles of
individual patients can be related to a selected set of kinetic
parameters associated with abnormalities in the underlying
processes of lipoprotein metabolism. In its present state, the model
poses various questions to answer and offers a platform for many
future applications aimed at understanding the reasons for inter-
individual variability, identifying new sub-fractions of potential
clinical relevance and a patient-oriented diagnosis of individual
lipid abnormalities.
Materials and Methods
Stochastic Model
We consider a system of N lipoprotein complexes ~Lpi, i = (1, …,
N), which are affected by M different kinetic processes Rm, m= (0,
…, M) in a unit volume V. Each lipoprotein complex ~Lpi is unique
with respect to its composition (nAi, nBi, nFi, nCi, nTi) where nXi is
the number of molecules of component X, XM{A,B,F,C,T}, in the
lipoprotein i.
All lipoprotein complexes ~Lpi may be present with ni identical
copies. The ni may be any non-negative integer number. As our
model includes the exchange of the components A and F with
plasma pools of free A and free F, respectively, and the exchange
of the components C and T by the cholesteryl ester transfer
protein (CETP) we also introduce the numbers nA, nF, nCETP(0),
nCETP(C) and nCETP(T) which denote the numbers of the respective
component in the plasma pool. The state of the system is uniquely
characterized by the vector ~n of all numbers ni and of all pool
components.
~n~ n1,n2, . . . ,nN ,nA,nF , . . . ,nCETP Tð Þ
  ð1Þ
The set of all thinkable vectors ~n constitutes the state space of the
system. Let P ~n,tð Þd~n be the probability to observe the system in a
small volume d~n in the state space, i.e. the probability to find
n01ƒn1vn01zdn1
..
.
n0NƒnNvn0NzdnN
n0AƒnAvn0AzdnA
..
.
n0CETP Tð ÞƒnCETP(T)vn0CETP Tð ÞzdnCETP Tð Þ
The function P ~n,tð Þ is the probability density of state ~n. It
contains all information about the evolution of the stochastic
system over time. We denote with Nfrom the set of states which
may be transformed to state ~n by a single reaction and with Nto
the set of all states which may be produced from ~n by a single
reaction. Consider, for example the reaction EffluxAi represent-
ing the uptake of cholesteryl ester from an A-particle of type i.
The event of this reaction would be to transform a particle of
type i to type i-C which has one C less than i. Therefore, by
action of the considered reaction the number ni is reduced by
one. At the same time, the number ni{C is increased by one (the
total number of A-particles in the system is not affected by the
considered reaction). Therefore, the set Nto created by a reaction
of type EffluxA (with arbitrary i) is the set of all states where one
arbitrary A-particle is missing and in exchange, an A-particle
with one less C is added. In the same manner the action of the
other reactions has to be considered. The equation governing
the evolution of the probability density P ~n,tð Þ—the master
equation—can be written
dP ~n,tð Þ
dt
~
X
~n0[Nfrom
r~n0?~nP ~n
0,tð Þ{
X
~n0[Nto
r~n?~n0P ~n,tð Þ ð2Þ
Here, r~n?~n0 denotes the rate of the reaction transforming the
state ~n to ~n0. The explicit expression for this would be very
complicated as we have to consider all possible results of the
action of 20 different reaction types and will, therefore, be
omitted here.
The Master equation (Equation 2) cannot be analytically solved.
Therefore, we determined approximative numerical solutions by
using Gillespie’s stochastic simulation algorithm [51].
Gillespie’s algorithm. The time evolution of the system is
described as a sequence of events taking place at discrete time
points. In each event, only one of the elementary processes is
carried out instantaneously thereby changing the state of the
system. The probability for reaction m to occur next is proportional
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to its rate am which is considered constant between the events. The
total probability rate a0 =Sam is a measure for the total activity in
the system. Two random numbers uniformly distributed over the
unit interval are generated to determine both the waiting time t
until the next reaction occurs and the reaction m which occurs after
the previously determined waiting time. Reaction m is
characterized both by its type (e.g. EffluxA) and by the
individual lipoprotein being its substrate. Execution of the
reaction changes the state of the system (either by changing the
number of lipoproteins or by altering the composition of one of
them). Thus, recalculation of the reaction probabilities for the new
state is needed, however, only for those am which were actually
affected by the system change. The simulation time is advanced to
t= t+t. The process is repeated until the steady state of the system
is reached or a different termination criterion is met. In our
calculations this required approximately five millions of such
consecutive single events. During the execution of the algorithm
the lifetime of each lipoprotein in the system is monitored. This
allows to calculate the average number of an individual lipoprotein
complex in the steady state.
Deterministic model. If the probability density function
P ~n,tð Þ is known expectation values ci(t) for the concentration of
lipoprotein complexes can be calculated according to
ci tð Þ~ 1
V
X
~n
niP ~n,tð Þ: ð3Þ
The summation goes over all possible states of the system, i.e. over
all legal combinations of ni.
Carrying out the calculation of the expectation values using the
Master equation (Equation 2) one obtains a system of first-order
differential equations for the time evolution of the concentration
vector~c tð Þ:
~c tð Þ~ c1 tð Þ,c2 tð Þ, . . . ,cN tð Þ,cA tð Þ,cF tð Þ,ð
cCETP 0ð Þ tð Þ,cCETP Cð Þ tð Þ,cCETP Tð Þ tð Þ
 ð4Þ
The differential equation for the time-evolution of the concentra-
tion of the i-th lipoprotein complex has the general form (similar to
the form of the master equation)
dci
dt
~f
zð Þ
i ~cð Þ{ci:f {ð Þi ~cð Þ ð5Þ
where f
zð Þ
i and f
{ð Þ
i comprise all processes that increase or
decrease the concentration ci, respectively. The stationary solution
of this system obeys the fix-point equation Equation 6:
ci~
1
n
f
zð Þ
i ~cð Þ
f
{ð Þ
i ~cð Þ
z 1{
1
n
 
ci ð6Þ
which was solved iteratively. l$1 is an integer factor that helps to
stabilize convergence, i.e. to overcome oscillations that may occur
during iteration procedure.
Density Profile Calculation
The density d of a lipoprotein complex is calculated as the sum
of the component’s molecular weights wi divided by the sum of the
component’s molecular volumes vi
d~
P
wini,jP
vini,j
ð7Þ
where i specifies the components (A, B, F, C, T, P) and ni,j is the
number of molecules of component i in the lipoprotein complex j.
The number of phospholipid molecules is estimated to fill the
calculated free volume within the lipoprotein surface (see Dataset
S1). Values of the molecular weights and volumes were taken from
literature and are listed in Table 4. From its amino acid
composition, apoB-100 is estimated to have a molecular mass of
513 kDa. The somewhat higher apparent molecular mass
(approximately 550 kDa) of the native protein is the result of
glycosylation. For the lipid components CE, PL and TG we used
average values because the molecular weight and volume may
vary depending on the chain length and type (saturated, mono- or
polyunsaturated) of the esterified fatty acids.
Experiments
Subjects. All laboratory assessments were performed at the
Department of Clinical Chemistry, University of Freiburg,
Germany. Lipid profiles of eleven randomly selected
normolipidemic subjects were measured under fasting
conditions. Normolipidemic concentration ranges of total plasma
lipoprotein components are given in as follows: 120–240 mg/dl
total cholesterol, 25–200 mg/dl triglycerides, 40–80 mg/dl free
cholesterol, 80–160 mg/dl cholesteryl ester, 100–300 mg/dl
phospholipids and 90–200 mg/dl for apolipoprotein A-I, 40–
70 mg/dl A-II, 30–150 mg/dl B-100, 1–10 mg/dl C-II, 5–
15 mg/dl C-III and 4–12 mg/dl E.
Lipoprotein separation. Lipoproteins were isolated from
plasma by sequential preparative ultracentrifugation according to
Baumstark [32].
Table 4. Data for density calculation.
Component Molecular Weight, g/mol Molecular Volume, ml/mol Reference
A 28,500 21,087 [59]
B 546,340 404,292 [60]
F 15,000 11,100
C (FC+CE) 583 605
T 859 947 [60]
P 786 773 [60]
The molecular weight of component F is averaged by taking individual molecular weights (see also [53]) of apoC isoforms, predominantly apoC-II (8.8 kDa) and C-III
(8.9 kDa), and apoE (34 kDa) in a specific set ratio. Similarly, a 1:2 ratio for cholesterol:cholesteryl ester (with molecular weights of 386 and 648 Da, respectively) is used
for the average molecular weight of component C. Molecular volumes were calculated using appropriate component’s specific volumes [54].
doi:10.1371/journal.pcbi.1000079.t004
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Recoveries of cholesterol after centrifugation of all lipoproteins
were .95%. The interassay coefficient of variance of the
determination of apoB in each of the six LDL subfractions was
#5% [8].
Lipoprotein chemistry. Cholesterol (C), triglyceride (T) and
phospholipid (P) concentrations were determined enzymatically
with the CHOD-PAP, GPO-PAP and PLD-PAP methods (Roche
Diagnostics, Mannheim, Germany), respectively. Concentrations
of apolipoproteins were determined by turbidimetry on a Wako 30
R analyzer (Wako Chemicals, Japan) using polyclonal antisera
(Rolf Greiner Biochemica, Germany) specific for the respective
antigens. For experimental details the reader is referred to [8].
Parameter Estimation
Predicted and experimental lipoprotein profiles were compared
by measuring the distance
E pð Þ~
X
i
wi x
exp
i {x
pred
i pð Þ
 2
ð8Þ
where p is the vector of the model parameters. x
pred
i pð Þ and xexpi
correspond to the simulated and measured concentrations of
lipoprotein constituents in the i-th density class (see Table 2),
respectively. wi is a weight that all the data points contribute
equally to the distance. Model parameters are adjusted by
minimizing the distance function (Equation 8). To avoid
trapping of the minimization procedure in local minima we
used Simulated Annealing (SA) as described in [52] to find the
global optimum.
Model Equations
For most reactions considered in the model, the exact kinetic
mechanism including all regulatory effects is not known.
Therefore, we used simple rate equations based on mass action
kinetics. They are summarized in Dataset S4. There is a simple
relationship between the values of the rate constants to be used in
the stochastic and the deterministic model. The numerical values
of rate constants of first-order reactions are identical in both types
of models. In the case of second order reactions, the stochastic rate
constant cm derives from the deterministic rate constant km by
cm~
km
NAV
ð9Þ
where NA is the Avogadro constant and V denotes the small sample
volume used in the stochastic simulation.
Supporting Information
Dataset S1 Calculating the Number of Phospholipids
Found at: doi:10.1371/journal.pcbi.1000079.s001 (0.03 MB PDF)
Dataset S2 Description of the Kinetic Processes Defined in the
Model
Found at: doi:10.1371/journal.pcbi.1000079.s002 (0.03 MB PDF)
Dataset S3 Explanations to the Model Parameter Values
Found at: doi:10.1371/journal.pcbi.1000079.s003 (0.06 MB PDF)
Dataset S4 Model Equations
Found at: doi:10.1371/journal.pcbi.1000079.s004 (0.03 MB PDF)
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